Transforming Growth Factor Beta-1 C-509T Polymorphism and Cancer Risk: A Meta-analysis of 55 Case-control Studies

  • Liu, Yang ;
  • Lin, Xian-Fan ;
  • Lin, Chun-Jing ;
  • Jin, Si-Si ;
  • Wu, Jin-Ming
  • Published : 2012.09.30


Aim: To investigate the association of transforming growth factor-beta 1 (TGF-${\beta}1$) C-509T polymorphism and susceptibility to cancer by means of meta-analysis. Methods: An extensive search was performed to identify eligible case-control studies investigating such a link. The strength of the association between TGF-${\beta}1$ C-509T polymorphism and cancer risk was assessed by pooled odds ratios (ORs) and 95%confidence intervals (95%CIs) in fixed or random effects models. Results: 55 published case-control studies with a total number of 21,639 cases and 28,460 controls were included. Overall, there was no association between TGF-${\beta}1$ C-509T and cancer risk in all genetic comparison models (TT vs. CC: OR=1.01, 95%CI=0.89-1.15; T vs. C: OR=1.01, 95%CI=0.94-1.07). However, a stratified analysis by cancer type indicated -509 T allele was significantly associated with decreased risk of colorectal cancer (CRC) (TT vs. CT/CC: OR=0.85, 95%CI=0.76-0.95), especially for Caucasians (TT vs. CT/CC: OR=0.83, 95%CI=0.71-0.98) and for population-based studies (TT vs. CT/CC: OR=0.78, 95%CI=0.68-0.89). Conclusion: This meta-analysis suggested that TGF-${\beta}1$ C-509T polymorphism might contribute to a decreased risk on colorectal cancer susceptibility, especially for Caucasians.


TGF-${\beta}1$;polymorphism;cancer risk;meta-analysis


  1. Amirghofran Z, Jalali SA, Ghaderi A, Hosseini SV (2009). Genetic polymorphism in the transforming growth factor beta1 gene (-509 C/T and -800 G/A) and colorectal cancer. Cancer Genet Cytogenet, 190, 21-5.
  2. Babyshkina N, Malinovskaya E, Stakheyeva M, et al (2011). Association of functional -509C>T polymorphism in the TGF-beta1 gene with infiltrating ductal breast carcinoma risk in a Russian Western Siberian population. Cancer Epidemiol, 35, 560-3.
  3. Bhayal AC, Prabhakar B, Rao KP, et al (2011). Role of transforming growth factor-beta1 -509 C/T promoter polymorphism in gastric cancer in south Indian population. Tumour Biol, 32, 1049-53.
  4. Blobe GC, Schiemann WP, Lodish HF (2000). Role of transforming growth factor beta in human disease. N Engl J Med, 342, 1350-8.
  5. Chen B, Zeng ZR, Ke B, et al (2011). Relationship between TGF${\beta}$1-509C/T gene polymorphism and traditional Chinese medical syndrome patterns in gastric cancer. J Guangzhou University Traditional Chin Med, 28, 339-43+48.
  6. Chung SJ, Kim JS, Jung HC, Song IS (2007). Transforming growth factor-[beta]1 -509T reduces risk of colorectal cancer, but not adenoma in Koreans. Cancer Sci, 98, 401-4.
  7. Cox DG, Penney K, Guo Q, et al (2007). TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses' Health Study. BMC Cancer, 7, 175.
  8. Crivello A, Giacalone A, Vaglica M, et al (2006). Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann N Y Acad Sci, 1089, 98-103.
  9. Dehaghani AS, Zamanpour T, Naeimi S, et al (2010). Genetic variation in TGF-beta 1 gene promoter and risk of gestational trophoblastic disease. J Reprod Med, 55, 151-6.
  10. Derynck R, Akhurst RJ, Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29, 117-29.
  11. Dunning AM, Ellis PD, McBride S, et al (2003). A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res, 63, 2610-5.
  12. Ewart-Toland A, Chan JM, Yuan J, et al (2004). A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer. Cancer Epidemiol Biomarkers Prev, 13, 759-64.
  13. Falleti E, Fabris C, Toniutto P, et al (2008). TGF-beta1 genotypes in cirrhosis: relationship with the occurrence of liver cancer. Cytokine, 44, 256-61.
  14. Grainger DJ, Heathcote K, Chiano M, et al (1999). Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet, 8, 93-7.
  15. Guan X, Zhao H, Niu J, et al (2009). The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. BMC Gastroenterol, 9, 77.
  16. Guo W, Dong Z, Guo Y, et al (2011). Polymorphisms of transforming growth factor-beta1 associated with increased risk of gastric cardia adenocarcinoma in north China. Int J Immunogenet, 38, 215-24.
  17. Healy J, Roy-Gagnon MH, Sinnett D (2009). No evidence for association between TGFB1 promoter SNPs and the risk of childhood pre-B acute lymphoblastic leukemia among French Canadians. Haematologica, 94, 1034-5.
  18. Hu S, Zhou G, Zhang L, et al (2012). The effects of functional polymorphisms in the TGFbeta1 gene on nasopharyngeal carcinoma susceptibility. Otolaryngol Head Neck Surg, 146, 579-84.
  19. Huang Y, Hao Y, Li B, et al (2011). Lack of significant association between TGF-beta1-590C/T polymorphism and breast cancer risk: a meta-analysis. Med Oncol, 28, 424-8.
  20. Jakubowska A, Jaworska K, Cybulski C, et al (2009). Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? Eur J Cancer, 45, 837-42.
  21. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  22. Jin G, Deng Y, Miao R, et al (2008). TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population. J Cancer Res Clin Oncol, 134, 345-51.
  23. Jin G, Wang L, Chen W, et al (2007). Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population. Int J Cancer, 120, 1330-5.
  24. Jin Q, Hemminki K, Grzybowska E, et al (2004). Polymorphisms and haplotype structures in genes for transforming growth factor beta1 and its receptors in familial and unselected breast cancers. Int J Cancer, 112, 94-9.
  25. Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 24, 2137-50.
  26. Kang D, Lee KM, Park SK, et al (2007). Lack of association of transforming growth factor-beta1 polymorphisms and haplotypes with prostate cancer risk in the prostate, lung, colorectal, and ovarian trial. Cancer Epidemiol Biomarkers Prev, 16, 1303-5.
  27. Kang HG, Chae MH, Park JM, et al (2006). Polymorphisms in TGF-beta1 gene and the risk of lung cancer. Lung Cancer, 52, 1-7.
  28. Li T, Cao BW, Dai Y, et al (2008). Correlation of transforming growth factor beta-1 gene polymorphisms C-509T and T869C and the risk of gastric cancer in China. J Gastroenterol Hepatol, 23, 638-42.
  29. Lin XD, Li C, Shi Y, et al (2010). Correlation of polymorphism of Nme1-1465 T>C and TGFbeta1-509 T>C with genetic susceptibility of gastric carcinoma. Zhonghua Bing Li Xue Za Zhi, 39, 681-5.
  30. Liu Y, Zhou W, Zhong DW (2012). Meta-analyses of the associations between four common TGF-beta1 genetic polymorphisms and risk of colorectal tumor. Tumour Biol, 33, 1191-9.
  31. Luedecking EK, DeKosky ST, Mehdi H, et al (2000). Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer's disease. Hum Genet, 106, 565-9.
  32. Macarthur M, Sharp L, Hold GL, et al (2005). The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev, 14, 1613-8.
  33. Massague J, Blain SW, Lo RS (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. Cell, 103, 295-309.
  34. Nikolova PN, Pawelec GP, Mihailova SM, et al (2007). Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population. Cancer Immunol Immunother, 56, 371-9.
  35. Niu H, Niu Z, Zhang XL, Chen ZL (2012). Absence of association between transforming growth factor B1 polymorphisms and gastric cancer: a meta-analysis. DNA Cell Biol, 31, 706-12.
  36. Niu W, Qi Y, Gao P, Zhu D (2010). Association of TGFB1 -509 C>T polymorphism with breast cancer: evidence from a meta-analysis involving 23,579 subjects. Breast Cancer Res Treat, 124, 243-9.
  37. Park KH, Lo Han SG, Whang YM, et al (2006). Single nucleotide polymorphisms of the TGFB1 gene and lung cancer risk in a Korean population. Cancer Genet Cytogenet, 169, 39-44.
  38. Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004). Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer, 4, 850-60.
  39. Purdue MP, Sakoda LC, Graubard BI, et al (2007). A case-control investigation of immune function gene polymorphisms and risk of testicular germ cell tumors. Cancer Epidemiol Biomarkers Prev, 16, 77-83.
  40. Qi P, Chen YM, Wang H, et al (2009). -509C>T polymorphism in the TGF-beta1 gene promoter, impact on the hepatocellular carcinoma risk in Chinese patients with chronic hepatitis B virus infection. Cancer Immunol Immunother, 58, 1433-40.
  41. Qi P, Ruan CP, Wang H, et al (2010). -509C>T polymorphism in the TGF-beta1 gene promoter is not associated with susceptibility to and progression of colorectal cancer in Chinese. Colorectal Dis, 12, 1153-8.
  42. Quarmby S, Fakhoury H, Levine E, et al (2003). Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol, 79, 137-43.
  43. Saha A, Gupta V, Bairwa NK, et al (2004). Transforming growth factor-beta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5'-untranslated-region and exon-1 polymorphisms. Eur J Immunogenet, 31, 37-42.
  44. Saltzman BS, Yamamoto JF, Decker R, et al (2008). Association of genetic variation in the transforming growth factor beta- 1 gene with serum levels and risk of colorectal neoplasia. Cancer Res, 68, 1236-44.
  45. Shin A, Shu XO, Cai Q, et al (2005). Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev, 14, 1567-70.
  46. Shu XO, Gao YT, Cai Q, et al (2004). Genetic polymorphisms in the TGF-beta 1 gene and breast cancer survival: a report from the Shanghai Breast Cancer Study. Cancer Res, 64, 836-9.
  47. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
  48. Singh H, Jain M, Mittal B (2009). Role of TGF-beta1 (-509C>T) promoter polymorphism in susceptibility to cervical cancer. Oncol Res, 18, 41-5.
  49. Slattery ML, Lundgreen A, Herrick JS, et al (2011). Genetic variation in the transforming growth factor-beta signaling pathway and survival after diagnosis with colon and rectal cancer. Cancer, 117, 4175-83.
  50. Tang B, Bottinger EP, Jakowlew SB, et al (1998). Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med, 4, 802-7.
  51. Tang RG, Pan XY, Long XK, et al (2005). Correlation between of serum level and genotype of TGF-${\beta}$1 in patients with esophageal cancer. Chin J Clin Lab Sci, 23, 266-68. (in Chinese)
  52. Vishnoi M, Pandey SN, Modi DR, et al (2008). Genetic susceptibility of epidermal growth factor +61A>G and transforming growth factor beta1 -509C>T gene polymorphisms with gallbladder cancer. Hum Immunol, 69, 360-7.
  53. Wei CL, Wu YG (2008). Association of TGF-${\beta}$1 gene single nucleotide polymorphism with ovarian cancer. Guangdong Med J, 29, 1369-71. (in Chinese)
  54. Wei LH, Chen FK, Tan ZQ, Chen H, D. (2007). Association of TGF-${\beta}$1 gene polymorphism with colorectal cancer. Tumor, 27, 383-85+405.
  55. Wei YS, Xu QQ, Wang CF, et al (2007). Genetic variation in transforming growth factor-beta1 gene associated with increased risk of esophageal squamous cell carcinoma. Tissue Antigens, 70, 464-9.
  56. Wei YS, Zhu YH, Du B, et al (2007). Association of transforming growth factor-beta1 gene polymorphisms with genetic susceptibility to nasopharyngeal carcinoma. Clin Chim Acta, 380, 165-9.
  57. Wu GY, Hasenberg T, Magdeburg R, et al (2009). Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J Surg, 33, 124-9.
  58. Wu GY, Lu Q, Hasenberg T, et al (2010). Association between EGF, TGF-{beta}1, TNF-{alpha} gene polymorphisms and cancer of the pancreatic head. Anticancer Res, 30, 5257-61.
  59. Wu HM, Fan YZ, Liu WF, et al (2008). Transforming growth factor-beta 1 gene C-509T polymorphism and genetic susceptibility to colorectal cancer. World Chin J Digestol, 16, 4020-23. (in Chinese)
  60. Xin Z, Zhang W, Xu A, et al (2012). Polymorphisms in the potential functional regions of the TGF-beta 1 and TGFbeta receptor genes and disease susceptibility in HBVrelated hepatocellular carcinoma patients. Mol Carcinog, 51, E123-31.
  61. Xu Y, Pasche B (2007). TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet, 16 Spec No 1, R14-20.
  62. Yang Y, Qiu XQ, Yu HP, et al (2011). Polymorphism of TGF-${\beta}$1 and IL-12B gene and risk of hepatocellular cancer in Guangxi: a case-control study. Chin J Public Health, 27, 1383-85. (in Chinese)
  63. Yu YH, Chen CX (2010). Association of transforming growth factor beta 1 gene polymorphisms with colorectal cancer. J Clin Int Med, 27, 490-3. (in Chinese)
  64. Yu YH, Chen CX, Huang QM, Zhang J (2010). Association of Transforming Growth Factor Beta 1 Gene Polymorphism and Gastroauodenal Diseases with Helicobaeter Pylori Infection. Chin J Clin Gastroenterol, 22, 273-76. (in Chinese)
  65. Zhang P, Di JZ, Zhu ZZ, et al (2008). Association of transforming growth factor-beta 1 polymorphisms with genetic susceptibility to TNM stage I or II gastric cancer. Jpn J Clin Oncol, 38, 861-6.
  66. Zhang Y, Liu B, Jin M, et al (2009). Genetic polymorphisms of transforming growth factor-beta1 and its receptors and colorectal cancer susceptibility: a population-based casecontrol study in China. Cancer Lett, 275, 102-8.
  67. Zhou Y, Jin GF, Jiang GJ, et al (2007). Correlations of polymorphisms of TGFB1 and TGFBR2 genes to genetic susceptibility to gastric cancer. Ai Zheng, 26, 581-5.

Cited by

  1. TGF-β1 −509C/T (or +869T/C) polymorphism might be not associated with hepatocellular carcinoma risk vol.34, pp.5, 2013,
  2. Association between TGF-β1 Polymorphisms and Head and Neck Cancer Risk: A Meta-Analysis vol.8, pp.1664-8021, 2017,